Treatment
- abiraterone
- anastrozole
- bicalutamide
- capecitabine
- CAPOX
- carboplatin
- cetuximab
- cisplatin
- crizotinib
- dacarbazine
- docetaxel
- doxorubicin
- epirubicin
- erlotinib
- everolimus
- exemestane
- fluorouracil
- flutamide
- FOLFOX
- FOLFIRI
- fulvestrant
- gefitinib
- gemcitabine
- goserelin
- imatinib
- irinotecan
- lapatinib
- letrozole
- leuprolide
- liposomal doxorubicin
- megestrol acetate
- nab-paclitaxel
- oxaliplatin
- paclitaxel
- panitumumab
- pemetrexed
- pertuzumab
- sorafenib
- sunitinib
- tamoxifen
- temozolomide
- temsirolimus
- topotecan
- toremifene
- trastuzumab
- vemurafenib
gemcitabine
Gemcitabine is metabolized intracellularly by nucleoside kinases to the active
diphosphate (dFdCDP) and triphosphate (dFdCTP) nucleosides. The cytotoxic effect of
gemcitabine is attributed to a combination of two actions of the diphosphate and the
triphosphate nucleosides which leads to inhibition of DNA synthesis. Gemcitabine
exhibits cell phase specificity, primarily killing cells undergoing DNA synthesis (S-phase)
and also blocking the progression of cells through the G1/S-phase boundary.
Gemcitabine is indicated* for treatment of ovarian cancer, breast cancer, NSCLC and
pancreatic cancer.
*Please refer to full prescribing information/package insert for precise indications.
Associated Tumor Types
